Cidara Therapeutics Reports Unfavorable Results of Phase 2 RADIANT Trial of CD101 Topical in VVC
21. Februar 2017 07:30 ET
|
Cidara Therapeutics, Inc.
Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track ...
Cidara Provides Corporate Update and Reports Third Quarter 2016 Financial Results
10. November 2016 16:10 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
11. August 2016 16:12 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other...
Cidara Reports Second Quarter 2015 Financial Results and Provides Corporate Update
11. August 2015 16:13 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections,...
Cidara Therapeutics to Present at the Wedbush PacGrow 2015 Healthcare Conference
05. August 2015 07:30 ET
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections,...